New Circumvent G2 provides the same great efficacious results you've come to expect, now with 5-month PCV2 duration of immunity. Plus, Circumvent G2 is the ONLY PCV2 vaccine approved for use in pigs as early as 3 days of age.
Efficacy Trial Data for Circumvent G2
Merck Animal Health is the only company to bring a PCV2 vaccine to market using a PCV2 and PRRS co-infection challenge model. This helps predict the ability of the vaccine to perform in real-world conditions.
With a history of success in controlling PCV2 infection around the world, the same antigen and adjuvant used in making other Circumvent vaccines were used in making Circumvent G2.
In both one-dose and two-dose efficacy studies, vaccinates and controls were challenged at 10 weeks of age. They were also co-mingled, resulting in continuous challenge for the vaccinated pigs because the control pigs started shedding large amounts of the virus 2 weeks post-challenge.
Both options of Circumvent G2:
- Induced PCV2 antibody titers
- Helped prevent or significantly reduce PCV2 viremia
- Reduced virus shedding by more than 100-fold
- Reduced the level of PCV2 infection in lymphoid tissues
See the full studies in the Efficacy Trial Data for Circumvent PCV G2 Technical Bulletin.Download PDF
DOI Trial Data for Circumvent G2
With protection lasting about 25% longer than its closest competitor, Circumvent G2 works until just prior to marketing.
In studies demonstrating its 5-month PCV2 duration of immunity (DOI), Circumvent G2 significantly reduced PCV2 viremia in pigs during the entire post-challenge monitoring period following a PCV2 and PRRS challenge 20 weeks after vaccination.
Circumvent G2 also significantly reduced virus shedding in pigs during the entire post-challenge monitoring period following a PCV2 and PRRS challenge 20 weeks after vaccination.
See the full results in the DOI Trial Data for Circumvent PCV G2 Technical Bulletin.Download PDF
Review of Circumvent Efficacy
The Circumvent product line has successfully and effectively protected against PCV2 for years. A review of efficacy data assures that Circumvent G2 is equally effective in the prevention of PCV2 viremia.
Merck Animal Health is the only company to use a PCV2 and PRRS co-infection challenge model. Plus, they use a natural promoter curing the challenge to ensure that pigs are susceptible to PCV2 infection. Although a devastating disease under field conditions, PCV2 is not easily infectious in laboratory challenge models.
All Circumvent products aid in the prevention of PCV2 viremia:
Learn more in the Review of Circumvent Efficacy Technical Bulletin. Download PDF